Abstract
The worldwide prevalence of hypertension is expected to increase from approximately 1 billion individuals in 2000 to over 1.5 billion in 2025 and is currently the most frequent medical diagnosis in the USA [1]. Not only is hypertension a powerful risk factor for cardiovascular disease, doubling the risk of mortality from coronary heart disease and stroke for every 20 mmHg increase in systolic blood pressure and 10 mmHg increase in diastolic pressure, but also is closely linked to the risk of developing type-2 diabetes.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment and control of hypertension in the United States 1988–2000. JAMA 2003;290:199–206.
Hayashi T, Tsumura K, Suematsu C, Okada K, Fujii S, Endo G. The Osaka Health Survey. Ann Intern Med 1999;131(1):21–26.
US Preventive Services Task Force. Screening for coronary heart disease: recommendation statement. Ann Intern Med. 2004;140:569–572.
United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type-2 diabetes. BMJ 1998;317:703–713.
Staessen JA, Fagard R, Thijs L. Randomised double blind comparison of placebo active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757–764.
Tuomilehto J, Lindstrom J, Eriksson JG. Prevention of type-2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343–1350.
Gifford RW. A missed opportunity; our failure to control hypertension optimally. J Clin Hypertens 2000;2:21–24.
DeSimone G, Roman MJ, Alderman MH. High pulse pressure as a marker for preclinical cardiovascular disease. Hypertension 2005;45:575–579.
United Kingdom Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 1998;317:703–771
Van Itllie TB. Health implications of overweight and obesity in the United States. Ann Intern Med 1985;103(6):983–988.
Hansson L, Zanchetti A, Carruthers SG. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension; principal results of the Hypertension Optimum (HOT) trial. Lancet 1998;351:1755–1762.
Hansson L, Zanchetti A, et al. for the HOT Study Group. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension. Lancet 1998;351:1755–1762.
Adler A, Stratton I, Neill H. Association of systolic blood pressure with macrovascular and microvascular complications of type-2 diabetes (UKPDS-36). BMJ 2000;321:412–419.
Curb JD, Pressel SL, et al. Effect of diuretic based antihypertensive treatment on cardiovascular risk in older diabetic patients with isolated systolic hypertension. JAMA 1996;276:1886–1892.
Basile J, Lackland D, et al. A statewide primary care approach to cardiovascular risk factor control in high risk diabetic and non diabetic patients with hypertension. J Clin Hypertens (Greenwich) 2004;6(1):18–25.
Ravid M, Lang R. et al. Long term renoprotective effect of angiotensin-converting enzyme inhibition on insulin dependent diabetes mellitus. Arch Intern Med 1996;156:286–289.
Goldbourt U, Behar S, Reicher-Reiss H, Agmon J, Keplinsky E. The bezafibrate infarction prevention (BIP) trial. Am J Cardiol 1993;71(11):909–915.
American Diabetes Association. Treatment of hypertension in adults with diabetes, Diabetes Care 2002;199–201:213–229.
American Association of Clinical Endocrinologists Ad Hoc Task Force for Standardized Production of Clinical Practice guidelines. AACE protocol for standardized production of clinical practice guidelines. Endocr Pract. 2004;10;353–361.
Lindholm L, Persson M, Alaupovic P,Carlberg V, Svensson A, Samuelsson O. The Antihypertesnive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE) study. Journal of Hypertension 2003;21(8):1563–1574.
Poole-Wilson P, Swedberg K, Cleland J, Lenarda A, Hanrath P, Komajda M. The Carvedilol or Metoprolol European (COMET) Trial. Lancet 2003;362(9377):7–13.
Bakris Gl, Fonseca V, Katholi RE. Metabolic effects of carvedilol vs. metoprolol in patients with type-2 diabetes mellitus and hypertension. GEMINI trial. JAMA 2004;292:2227–2236.
Giugliano D, Acampora R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin dependent diabetes mellitus and hypertension. Ann Intern Med 1997;126:955–959.
Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. (ABCD Trial). N Engl J Med 1998;338:645–652.
Tatti P, Pahor M, et al. Outcome results of the fosinopril versus amlodipine cardiovascular randomized events trial (FACET) in patients with hypertension and non-insulin dependent diabetes mellitus. Diabetes Care 1998;21:597–603.
Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure: The sixth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997;154:2413–2446.
Hansson L, Lund-Johansen P, Hedner T. Randomized trial of effects of calcium antagonists compared with diuretics and beta blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:366–372.
Brown MJ, Palmer CR, Castaigne A. Morbidity and mortality in patients randomized to double blind treatment with a long acting calcium channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a goal in Hypertension treatment (INSIGHT). Lancet 2000;356:366–372.
Walker WG, Herman J, et al. Elevated blood pressure and angiotensin II are associated with accelerated loss of renal function in diabetic nephropathy. Trans Am Clin Climatol Assoc 1985;97:94–104.
Brenner BM, Cooper ME, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–869.
Bakris GL, Williams M, et al. Special Report: Preserving renal function in adults with hypertension and diabetes: A consensus approach. Am J kidney Dis. 2000;36:661.
Oh B, Mitchell J, Herron J, Chung J. Khan M. Aliskiren, an oral rennin inhibitor, provides dose dependent efficacy and sustained 24 hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007;49(11):1157–1163.
Duprez D. Aliskiren, the next innovation in the rennin-angiotensin-aldosteronesystem blockade. Aging Health 2009;3(5):269–279.
Tuomilehto J, et al. Effects of calcium channel blockade in older patients with diabetes and systolic hypertension. Lancet 1997;6:357–364.
Estacio, RO, Jeffers BW, et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23(Suppl 2):B54–B64.
Materson BJ, Reda DJ, Cushman WC. Single drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of veterans Affairs Cooperative Study group on Antihypertensive Agents. N Engl J Med 1993;328:914–921.
Adler AI, Stratton IM, et al. Association of systolic blood pressure with marovascular and microvascular complications of type 2 diabetes. BMJ 2000; 321(7258):405–412.
Laffel LMB, McGill JB, et al. The beneficial effect of angiotensin converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am J Med 1995;99:497–540.
Lewis EJ, Hunsiker LG, et al. Renoprotective effect of the angiotensin receptor blockers irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–860.
Reid CM, Ryan P, Nelson M. General practitioner participation in the second Australian National Blood Pressure Study (ANBP2). Clin Exp Pharmacol Physiol 2001;28:663–667.
Solomon S, Rice M, Jablonski K, Jose P, Domanski M. Renal function and effectiveness of angiotensin converting enzyme inhibitor therapy in patients with stable coronary artery disease in the Prevention of Events with ACE inhibition (PEACE) Trial. Circulation 2006;114:26–31.
Anderson S, Tarnow L, Rossing P, et al. Renoprotective effects of angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. Kidney Int 2000;57:601–606.
Cohn JN, Tognoni G. A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. The (VALHeFt) Trial. N Engl J Med 2001;345:1667–1675.
Pitt B, Poole-Wilson PA, Segal R. Effects of Losartan compared with captopril on mortality in patients with symptomatic heart failure: the Losartan Heart Failure Survival Study (ELITE II). Lancet 2000;355:1582–1587.
Chobanian AV, Bakris G, Black HR. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of Hypertension JAMA 2003;289:2560–2571
Vijan S, et al. Treatment of hypertension in type 2 diabetes mellitus: blood pressue goals, choice of agents and setting priorities in diabetes care. Ann Int Med 2003;138:593–602.
American Diabetes Association. Hypertension in type-2 diabetes. Diabetes Care 2007;30:S4–S41.
Chobanian AV. Interrelationship of hypertension and type-2 diabetes. Hypertension 2003;42:1206–1252.
Supplementary Readings
Bell DSH. Beta-adrenergic blocking agents in patients with diabetes – friend or foe? Endocr Pract 1999;5:51–53.
Chirstensen PK, Gall MA, et al. Course of glomerular filtration rate in albuminuric type 2 diabetic patients with or without diabetic glomerulopathy. Diabetes Care 2000;23(Suppl 2):B4–B20.
Cooper M, Johnston C. Optimizing treatment of hypertension in patients with diabetes. JAMA 2000;283(24):3177–3179.
Cooper ME, Pathogenesis, prevention and treatment of diabetic nephropathy. Lancet 1998;352:213–219.
DeStefano F, Ford ES, et al. Risk factors for coronary heart disease mortality among persons with diabetes. Ann Epidemiol 1993:3(1):27–34.
Elkeles RS, Diamond JR, et al. Caridovasccular outcomes in type 2 diabetes. Diabetes Care 1992;15:820–825.
Fu Y, Deedwania P. Management of hypertensive patients with diabetes mellitus. Cin Ger 2001;9(7):22–36.
Factor SM, Minase T, et al. Clinical and Morphological features of human hypertensive diabetic cardiomyopathy. Am Heart J 1980;99:446–458.
Giese M, Lackland DT, et al. The hypertension initiative of South Carolina. Promoting cardiovascular health through better blood pressure control. J S C Med Assoc 2001;97:57–62.
Gustaffson I, et al. Effect of the angiotensin converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. J Am Coll Cardiol 1999;34:83–89.
Harris MI. Racial and ethnic differences in health care access and health outcomes for adults with type 2 diabetes. Diabetes Care 2001;24:454–459.
Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253–259.
Larme AC, Pugh JA, et al. Attitudes of primary care providers toward diabetes: barriers to guideline implementation. Diabetes Care 1998;21:1391–1396.
Lazarus JM, Bourgoignie JJ, et al. Achievement and safety of a low BP goal in chronic renal disease. Hypertension 1997;29:641–650.
Parving HH, Lehnert H, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870–878.
Pyorala K, Pedersen TR, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary artery disease. Diabetes Care 1997;20:614–620.
Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999;341(19):1127–1133.
Staessen JA, Fagard R, et al. Randomized double blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757–764.
Sowers JR, Lester MA. Diabetes and cardiovascular disease. Diabetes Care 1999; 22(Suppl 3):C14–C20.
Sniderman A, Michel C, et al. Heart disease in patients with diabetes mellitus. J Clin Epidemiol 1992;45:1357–1370.
Van Hoeven KH, et al. A comparison of the pathological spectrum of hypertensive, diabetic and hypertensive diabetic heart disease. Circulation 1990;82:848–855.
Author information
Authors and Affiliations
Additional information
Diplomate American Board of Internal Medicine
Diplomate American Board of Clinical Lipidology
Diplomate American Board of Vascular Medicine
Clinical Hypertension Specialist (American Society of Hypertension Certified)
Vascular Ultrasound (American Registry of Diagnostic Sonography Certified)
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Codario, R.A. (2011). Hypertension in Diabetics. In: Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome. Current Clinical Practice. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-441-8_12
Download citation
DOI: https://doi.org/10.1007/978-1-60327-441-8_12
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60327-440-1
Online ISBN: 978-1-60327-441-8
eBook Packages: MedicineMedicine (R0)